IPP Bureau
Cipla receives final approval for Lanreotide injection
By IPP Bureau - December 20, 2021
It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumours
WHO grants EUL for Covovax
By IPP Bureau - December 20, 2021
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
Gamaleya claims the Sputnik V perfect booster against Omicron
By IPP Bureau - December 20, 2021
Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response
Merck’s tepmetko receives positive CHMP opinion in Europe
By IPP Bureau - December 20, 2021
The medicine is the first and only oral MET inhibitor to receive CHMP positive opinion in Europe for adult patients with advanced NSCLC harbouring alterations leading to METex14 skipping
Beghou Consulting opens office in Pune to assist life sciences firms
By IPP Bureau - December 20, 2021
The company will collaborate with U.S.-based colleagues to help life sciences companies improve commercial effectiveness
ICMR invites EOI for Omicron detection kits
By IPP Bureau - December 20, 2021
The Indian Council of Medical Research (ICMR), intends to enter into non-exclusive agreements with companies
Moderna says Covid-19 booster dose works against Omicron in lab study
By IPP Bureau - December 20, 2021
Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold
TeleRay and Radiobotics to provide radiology AI
By IPP Bureau - December 20, 2021
TeleRay partners with Radiobotics, adding Artificial Intelligence to their pre-existing integrated best-in-class medical image and patient information distribution platform
Astra Zeneca’s antibody combination to prevent Covid-19 neutralises Omicron variant
By IPP Bureau - December 17, 2021
The study was performed independently by investigators at the US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research
Novel Concepts Medical’s formula disrupts Covid-19 spike protein
By IPP Bureau - December 17, 2021
The company is now ready to offer clinical testing anywhere in the world after early case studies conducted in Israel have demonstrated recovery within 48 hours
EMA approves Pfizer’s Covid-19 anti-viral candidate
By IPP Bureau - December 17, 2021
EMA’s CHMP advice states that Paxlovid can be used for treatment of adults with Covid-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease
Boyd Corporation acquires MBK Tape Solutions
By IPP Bureau - December 17, 2021
Medical footprint expansion with deeper medical grade skin contact material science expertise
Alloy Therapeutics acquires deepCDR Biologics to bring ML into drug discovery
By IPP Bureau - December 17, 2021
The deepCDR engine combines deep sequencing and deep learning methods with a proprietary mammalian display process to select from a wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles
New data suggests Covaxin generates robust memory to Covid-19 and variants six months after vaccination
By IPP Bureau - December 17, 2021
Effectiveness of Covaxin against the Omicron variant is currently being studied
Noorik Biopharma signs contract with Switzerland to develop ambrisentan to treat severe Covid-19
By IPP Bureau - December 16, 2021
The primary objective of the ongoing trial is to determine whether ambrisentan can prevent the progression to respiratory failure and reduce the need for mechanical ventilation, among others
